Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioCryst Pharmaceuticals, Inc. (BCRX) had Revenue of $450.71M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$450.71M
Net Income	$-88.88M
Cost of Goods Sold	$12.27M
Gross Profit	$438.44M
Operating Expenses	$453.25M
Operating Income	$-2.54M
Non-Operating Income/Expense	$-84.41M
Pre-Tax Income	$-86.95M
Normalized Pre-Tax Income	$-86.95M
Income after Taxes	$-88.88M
Income from Continuous Operations	$-88.88M
Consolidated Net Income/Loss	$-88.88M
Normalized Income after Taxes	$-88.88M
EBIT	$-2.54M
EBITDA	$-12.77M
Weighted-Average Shares Outstanding (Basic)	206.70M
Weighted-Average Shares Outstanding (Diluted)	206.70M
Earnings per Share (EPS) (Basic)	$-0.43
Earnings per Share (EPS) (Diluted)	$-0.43
Balance Sheet Financials
Current Assets	$421.97M
Property, Plant, and Equipment	$7.78M
Long-Term Assets	$68.45M
Total Assets	$490.42M
Current Liabilities	$160.38M
Long-Term Debt	$798.05M
Long-Term Liabilities	$805.97M
Total Liabilities	$966.35M
Common Equity	$-475.93M
Tangible Shareholders Equity	$-475.93M
Shareholders Equity	$-475.93M
Common Shares Outstanding	208.54M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-52.02M
Cash Flow from Investing Activities	$52.59M
Cash Flow from Financial Activities	$-5.76M
Beginning Cash	$112.45M
End Cash	$106.32M
Increase/Decrease in Cash	$-6.12M
Stock-Based Compensation	$65.41M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.63
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.48
Debt to Equity Ratio	-1.75
Gross Margin	97.28%
Operating Margin	-0.56%
EBIT Margin	-0.56%
EBITDA Margin	-2.83%
Pre-Tax Profit Margin	-19.29%
Profit Margin	-19.72%
Free Cash Flow	$-53.14M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.92
Inventory Turnover	1.52
Receiveable Turnover	5.70
Days Sales in Receivables	64.03
Return on Equity	18.68%
Return on Tangible Equity	18.68%
Return on Assets	-18.12%
Return on Investments	-27.59%
Book Value Per Share	$-2.28
Free Cash Flow per Share	$-0.26
Operating Cash Flow per Share	$-0.25

Data from Zacks Investment Research, Inc.